论文部分内容阅读
1980年 Bast 等用人浆液性囊腺癌的腹水细胞系OVCA_(433)与 BALB/C 接种于小鼠,制成抗上皮性卵巢癌的新单克隆抗体(OC_(125)),用这一抗体检测的抗原(CA_(125))与存在于胚胎期体腔上皮的糖蛋白有关。免疫组织化学研究发现这一抗原存在于上皮性卵巢肿瘤的腺腔上皮细胞膜上。1983年发现在人血清中存在着对本抗体有反应的 CA_(125)抗原,卵巢癌患者血清中多呈高值,通过治疗,其血清水平与病理的变化有明显的相关性。本文对卵巢癌及其它各种疾病作血清 CA_(125)测定研究。
In 1980, Bast et al. Inoculated mice with serous cytoplasmic cells OVCA_ (433) and BALB / C into human serous cystadenocarcinoma to make a new monoclonal antibody (OC 125) against epithelial ovarian cancer. Using this antibody The detected antigen (CA_ (125)) was related to the glycoprotein present in the epithelial cells of the embryonic stage. Immunohistochemical study found that this antigen exists in epithelial ovarian epithelial cell membrane epithelial cells. In 1983, it was found that CA125 (125) antigen was present in human serum and the serum of patients with ovarian cancer was mostly high. Through the treatment, there was a clear correlation between serum level and pathological changes. In this paper, ovarian cancer and other diseases for the determination of serum CA_ (125).